|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue | ||
| Product revenue | ||
| Service revenue | ||
| Total revenue | ||
| Cost of revenue | ||
| Product revenue | ||
| Service revenue | ||
| Total cost of revenue | ||
| Gross profit | ||
| Other net income | ||
| Research and development expenses (including research and development expenses from a related party of RMB60,789, RMB68,922 and RMB63,605 for the years ended December 31, 2023, 2024 and 2025, respectively) | ||
| Administrative expenses | ||
| Selling expenses | ||
| Impairment loss on receivables and contract assets (including provision of impairment loss of RMB1,292 and RMB160 for the years ended December 31, 2023 and 2024, respectively, and reversal of impairment loss of RMB335 on receivables from related parties for the year ended December 31, 2025) | ||
| Operating loss | ||
| Net foreign exchange gain | ||
| Net foreign exchange gain/(loss) | ||
| Interest income | ||
| Fair value changes of financial assets at fair value through profit or loss ("FVTPL") | ||
| Other finance costs | ||
| Inducement charges of warrants | ||
| Fair value changes of financial liabilities measured at FVTPL | ||
| Changes in the carrying amounts of preferred shares and other financial instruments subject to redemption and other preferential rights | ||
| Loss before taxation | ||
| Income tax | ||
| Loss for the year | ||
| Loss attributable to shareholders of the Company | ||
| Loss per ordinary share | ||
| Basic loss per Class A and Class B ordinary share (in RMB) | ||
| Diluted loss per Class A and Class B ordinary share (in RMB) |
Loading...
